AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2013
Feb 5, 2013
30583_dirs_2013-02-05_f383f83f-f572-4df7-bceb-050fee0bc5c7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2013-02-04
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-02-04 | Common Stock | M | 2000 | $12.99 | Acquired | 155691 | Direct |
| 2013-02-04 | Common Stock | S | 2000 | $55.7662 | Disposed | 153691 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-02-04 | Stock Option (right to buy) Common Stock | $12.99 | M | 2000 | Disposed | 2016-05-10 | Common Stock (2000) | Direct |
Footnotes
F1: Transaction made pursuant to a Rule 10b5-1 Trading plan executed on August 10, 2012.
F2: The price in Column 4 is a weighted average price. The prices actually received ranged from $55.58 to $55.925. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Original option grant vests 6/48th on November 11, 2006 and 1/48th on the 11th day of every month thereafter.